DATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGODATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGO
Home/Compounds/Secretin (Synthetic Human)
OtherFDA approvedRx required

Secretin (Synthetic Human)

Also known as: ChiRhoStim · SecreFlo
Brands: ChiRhoStim · SecreFlo

Synthetic human 27-amino-acid secretin used diagnostically for pancreatic disorders and gastrinomas.

A
Grade A
Multiple human RCTs
Human studies0
PubMed citations0
Routeintravenous
Regulatory (US)FDA approved · Rx
Last verified2 days ago

Mechanism of action

Binds secretin receptor on pancreatic ductal cells. Stimulates bicarbonate-rich pancreatic fluid secretion; also used to provoke gastrin release in suspected gastrinoma.

Evidence summary

0
Human studies
0
PubMed citations
19
Clinical trials
A
Evidence grade

Evidence summary in progress. See the citations section below for the underlying research papers.

Dosing protocols

Educational information only. Consult a licensed provider before using any peptide.
Administration routes
intravenous

Side effects & safety

From the FDA label
Source
nauseapancreatitisvomiting

Terms pulled directly from the referenced source. We don't fabricate frequencies — when a label doesn't publish a percentage, we don't either.

Interactions

No documented drug interactions on file.

Regulatory status

United States
FDA approved

FDA approved for diagnosis of pancreatic exocrine dysfunction, gastrinoma, and facilitation of ERCP (ChiRhoStim)

Compounding
Not permitted

Not available via 503A/503B compounding pharmacies.

Regulatory data last verified 4/19/2026

Clinical trials

NCT07285863An Open-Label Study On The Effects Of Human Secretin For Injection (CHIROSTIM) On Pancreatic Fluid Composition In Normal Human Volunteer ParticipantsNot Yet Recruiting · Phase 4 · Exocrine Pancreatic Insufficiency · n=24NCT04231279A Phase II Study to Identify the Role of Exocrine Pancreatic Insufficiency in Pediatric Patients With Abdominal Pain (RAP) Who Are Undergoing Upper Endoscopy Using Synthetic Human SecretinTerminated · Phase 3 · Abdominal Pain · n=27NCT00216294An Open-Label, Dose Escalation, Pilot Study to Assess the Safety and Efficacy of Subcutaneous RG1068 (Synthetic Human Secretin) in Patients With Obsessive Compulsive Disorder (OCD)Completed · Phase 2 · Obsessive Compulsive Disorder (OCD) · n=12NCT03404661Optical and Biochemical Biomarkers in Early Pancreatic Cancer Significance: A Prospective StudyCompleted · Pancreatic Cancer · n=346NCT01371240Evaluation of Efficiency of Secretin-Assisted Computed Tomography Scan and Secretin-Assisted Magnetic Resonance Imaging in Improving Pancreatic Enhancement and Tumor Conspicuity: Prospective StudyWithdrawn · Phase 1 · Pancreas CancerNCT00438906Screening for Early Pancreatic NeoplasiaCompleted · Pancreatic Neoplasm · n=200NCT03686618A Phase II Study to Establish the Efficacy of Synthetic Human SecretiN in Human Acute Pancreatitis (SNAP) StudyUnknown · Phase 2 · Pancreatitis, Acute · n=40NCT01094561Secretin-Stimulated MRCP as an Early Screening Modality for Pancreatic Ductal Abnormalities in Patients at High Risk for Pancreatic Adenocarcinoma: A Pilot StudyCompleted · N/A · Pancreatic Cancer · n=23NCT01094626MRI With Secretin Enhancement to Increase Conspicuity of Pancreatic CancerWithdrawn · N/A · Pancreatic CancerNCT01094535MRCP With Secretin Stimulation for the Evaluation of Pancreatic Endocrine and Exocrine Function Following Surgical Resection for Pancreatic AdenocarcinomaWithdrawn · N/A · Pancreatic CancerNCT00587132Pilot Study Using Secretin and Iodinated Intravenous Contrast and 64-Channel CT in Patients at High Risk for Pancreatic AdenocarcinomaTerminated · Phase 1 · Pancreatic Cancer · n=4NCT01094600Comparison of Secretin Enhanced MRCP to Endoscopic Pancreatic Function Testing in Diagnosing Exocrine Insufficiency in Patients Who Have Undergone Pancreas Cancer ResectionWithdrawn · N/A · Pancreatic Cancer

Showing 12 of 19 indexed studies. View all on ClinicalTrials.gov →

Citations

No citations indexed yet.